{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.3","upperLimit":"2.8","value":"1.5"},{"groupId":"OG001","lowerLimit":"1.3","upperLimit":"2.7","value":"1.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"description":"Time to response is defined as the time from the date of the first dose of study intervention until the date of first documented objective response, which is subsequently confirmed per RECIST 1.1","dispersionType":"Inter-Quartile Range","groups":[{"description":"Final Analysis with DCO on 06May2024","id":"OG000","title":"TNBC Cohort"},{"description":"Final Analysis with DCO on 27Nov2024","id":"OG001","title":"NSCLC Cohort"}],"paramType":"MEDIAN","populationDescription":"RES: Enrolled participants who received at least one dose of study intervention and had measurable disease at baseline by ICR. The analysis for TTR assessed by ICR was based on the responders in the RES of each cohort.","reportingStatus":"POSTED","timeFrame":"TNBC cohort: from enrollment to 13 months post last subject dose with a median of 12 months follow up. NSCLC cohort: from enrollment to 20 months post last subject dose with a median of 16.7 months follow up.","title":"Time To Response (TTR) , Assessed by ICR","type":"SECONDARY","unitOfMeasure":"Month"}